The aim of this study was to explore the impactof real-world, off-label, patient controlled CGM use in combination withcontinuous subcutaneous insulin infusion (CSII) on costs and effects inpatients with type 1 diabetes in a Swedish clinic. The gene discussed is INS; the disease is type 1 diabetes mellitus.